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Abstract
Background: Two novel HER2 aptamers were recently selected with great potential for the in vitro diagnosis of
HER2-positive cancer. The goal of this study was to examine the in vivo diagnostic potential of these HER2
aptamers.
Methods: Both HER2 aptamers were radiolabelled with 68Ga, injected in mice bearing a HER2-positive and
HER2-negative tumour and evaluated by PET/MRI.
Results: Ex vivo bio distribution analysis revealed high uptake in the blood, tissues and organs, except the brain.
Interestingly, this high uptake was explained by the slow blood clearance due to non-specific aptamer binding to
blood proteins. We observed accumulation of radioactivity in both tumours in time. Although higher uptake in the
HER2-positive tumour compared to the HER2-negative tumour was observed, this was accompanied with more
necrosis in the HER2-negative tumour, which was observed by 18FDG PET/CT.
Conclusion: This work presents a first step towards the development of 68Ga-labelled aptamers for molecular
cancer imaging.
Keywords Aptamers; HER2 receptor; 68Ga; PET imaging; Bio-
distribution; Tumor-targeting
Introduction
Molecular cancer imaging provides information about all diseased
sites in the body (primary tumour and metastases), and avoids biopsy
sampling errors due to tumour heterogeneity (within the primary
tumor and between the primary tumour and the metastases). It also
provides useful targeting and dosimetry information which helps to
select the most effective (targeted) cancer therapy regimen. As such,
molecular cancer imaging enables the detection, staging, treatment
response prediction and treatment follow-up in an accurate and non-
invasive way.
One molecular target with high potential for targeted cancer
therapy and imaging is the human epidermal growth factor receptor 2
(HER2). HER2 gene amplification and protein overexpression is
present in 20% to 25% of all breast cancers, and is associated with poor
patient prognosis [1,2]. HER2 has no natural ligands, but monoclonal
antibodies and peptides that are able to bind HER2 have been
developed. For imaging purposes, full-length antibodies (150 kDa) are
less suitable due to slow extravasation and tumour penetration as well
as slow clearance of unbound antibody from blood.
Smaller targeting molecules generally provide faster tumour
localization and more rapid clearance from blood and healthy tissues,
resulting in higher image contrast at early time points after injection.
Smaller molecules also can have improved extravasation and increased
tumour penetration [3,4]. This was demonstrated by targeting HER2
using antibody fragments (10 kDa to 60 kDa) [5-7] and small proteins
(5 kDa to 25 kDa) [8-10].
Aptamers provide a potential alternative to the existing protein-
based targeting molecules. Aptamers are small (5 kDa to 15 kDa), non-
coding, single-stranded nucleic acid (DNA or RNA) molecules that
mimic antibodies in their ability to bind to a specific target. They fold
into three-dimensional structures which allow them to bind a specific
target with high affinity and specificity. Aptamers possess several
advantages over antibodies and proteins such as easy and inexpensive
chemical synthesis, low immunogenicity and non-toxicity. Several
aptamers targeting HER2 have been reported [11-18]. So far, only one
of these aptamers has been radiolabelled (with 99mTc) and its
biodistribution was evaluated ex vivo [19,20].
The use of smaller molecules with fast pharmacokinetics, such as
aptamers, allows radiolabelling with radionuclides with a shorter
physical half-life. Regarding diagnostic applications, the use of short-
lived radionuclides is beneficial in terms of patient comfort, radiation
protection and waste management. In PET imaging, 68Ga is the
radionuclide of choice because of its generator availability, easy and
stable radiochemistry and appropriate physical half-life (67.71 min).
Although of demonstrated utility in preclinical and limited clinical
studies, so far, no 68Ga-radiolabelled pharmaceutical has been
approved by the FDA or EMA [21]. However, the market approval of
the first 68Ge-68Ga generator in 2014 triggered a new and high interest
in the use of 68Ga. Finally, 68Ga is an attractive radionuclide in the view
of theranostics, as it can be easily replaced by the therapeutic
radionuclides 177Lu or 90Y [22].
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Recently, we reported the selection of two novel single-stranded
DNA aptamers with high targeting efficacy towards HER2 in vitro
[23,24]. The goal of this study was to demonstrate the feasibility of
these HER2 aptamers for in vivo tumour imaging. To this end, we
turned both HER2 aptamers into PET imaging agents by radiolabelling
them with 68Ga. Subsequently, we evaluated the ex vivo biodistribution
and tumour targeting properties by PET/MRI imaging.
Materials and Methods
Cell lines and cell culture
Human adherent cancer cell lines MDA-MB-231 (breast
adenocarcinoma) and SKOV3 (ovarian adenocarcinoma) were
purchased from American Type Cell Culture (ATCC). SKOV3 cells
were maintained in McCoy’s 5A culture medium (ATCC)
supplemented with 20% (v/v) fetal bovine serum (FBS) (Gibco) and
incubated in a humidified incubator at 37°C in the presence of 5% CO2
in air. MDA-MB-231 cells were maintained in Leibovitz’s L-15 culture
medium (ATCC) supplemented with 10% (v/v) FBS (Gibco) and 100
units/mL, penicillin and 100 µg/mL streptomycin 3232 (Gibco). MDA-
MB-231 cells were incubated in a humidified incubator at 37°C in
100% air. All cell lines were dissociated from the culture flask using 5
mM ethylenediaminetetraacetic acid (EDTA, Sigma-Aldrich).
Aptamers
Experiments were performed using the HER2 aptamer HeA2_3 (5’-
TCT AAA AGG ATT CTT CCC AAG GGG ATC CAA TTC AAA
CAG C-3’) or HeA2_1 (5’-ATT AAG AAC CAT CAC TCT TCC AAA
TGG ATA TAC GAC TGG G-3’) [23]. A negative control aptamer of
the same sequence length was also used (5’-CCC TTT TAC ACA ACC
ATC GAC ATA ACT AAA ACC ACC ACT G-3’). Aptamer sequences
were chemically synthesized by Integrated DNA Technologies (IDT).
Plasma stability assay
The susceptibility to nuclease-mediated degradation of aptamer
HeA2_3 was analyzed by a plasma stability assay. In addition, the
stability of aptamer HeA2_3 with additional modifications at its
terminal ends was evaluated. Aptamer HeA2_3_NOTA was
synthesized bearing a hexyldisulfide group at its 5’ end. Conjugation to
maleimide-NOTA was described as previously reported [24]. Aptamer
HeA2_3_NOTA_Inverted T was synthesized with a 5’ hexyldisulfide
group for conjugation to maleimide-NOTA and a 3’ inverted
thymidine.
The aptamer samples (1 nmol) were incubated with an equal volume
of isolated mouse plasma (obtained in EDTA microtubes according to
the manufacturer’s protocol, Kent Scientific) and incubated at 37°C for
a total of 12 h. At regular time points, aliquots were taken and mixed
with equal volumes of stop solution (8 M urea, 50 mM EDTA) and
frozen at -20°C. The samples (13.3 pmol aptamer each) were separated
on a 15% pre-casted Tris-borate-EDTA (TBE)-Urea polyacrylamide gel
(Mini-Protean, Biorad) at 300 V for 60 min. Next, the gels were stained
using a 3X GelRed (Biotium) in 0.1 M NaCl post-staining solution and
visualized at 254 nm using the Fusion-FX system (Fisher Biotec).
Quantification of the bands was performed using Bio-1-D software
(Vilber Lourmat). The aptamer half-lives were calculated by fitting the
curve to the non-linear one-phase decay model (equation y=y0-(kx)
with y0=initial band intensity, k=rate constant, half-life=ln2/k) (Graph
Pad). All samples were performed in triplicate. Migration of the
aptamer bands was compared to migration of the Ultra-Low Range
Gene Ruler DNA ladder (Thermo Scientific).
In vivo studies
Animals: Five weeks old female hairless non-obese diabetic severe
combined immunodeficient (NOD.Cg-PrkdcscidHrhr/NCrHsd) mice
were purchased from Harlan (Indianapolis, IN, USA). Mice were
housed together (3 to 4 mice per cage) in individual ventilated cages
and were kept under controlled conditions of 12:12 hour light:dark
cycle, 22 ± 2°C and 50 ± 5% relative humidity. The mice were fed ad
libitum with irradiated rodent diet (Teklad, Harlan Laboratories) and
autoclaved water. The animals were housed at the animal facility of
SCK•CEN in accordance with the Ethical Committee Animal Studies
of Medanex Clinic (EC_MxCl_2014_034). All animal experiments
were done in compliance with the NIH Guides for the Care and Use of
Laboratory Animals and were approved by the Ethical Committee of
the University of Liège.
Tumour inoculation: Mice were inoculated subcutaneously in the
hind leg with a 100 µL cell suspension composed of 50 µL cells in cell
culture medium and 50 µL Matrigel basement membrane matrix high
concentration (Corning) [25]. MDA-MB-231 cells (3 × 106) were
injected into the right flank area at the age of 6 weeks and SKOV3 cells
(1.5 × 106 ) were injected into the left flank area at the age of 7 weeks.
Tumour dimensions (largest diameter=a, smallest diameter=b) were
measured using a digital calliper (VWR) and calculated using the
following equation: volume (mm³)=a × b² × 0.5. Tumour volume and
animal weight were carefully monitored two to three times per week.
Aptamer radiolabelling: Radiolabelling was performed as described
before [26]. Briefly, the aptamer was functionalized with a disulfide
group and conjugated to MMA-NOTA. HPLC and ESI-MS analyses
indicated successful conjugation. 68Ga was eluted from a 68Ge-68Ga
generator (IRE-Elit) using 1.2 mL 0.1 N HCl, purified using 100 mg
strong-cation exchange Chromabond cartridges (Machery-Nagel), and
subsequently eluted with 250 µL 5 M NaCl (in 0.1 N HCl).
Radiolabelling was performed using 2.5 nmol lyophilized aptamer in
300 µL HEPES buffer (pH 4.4). A 100 µL fraction 68Ga was added to
the aptamer and incubated for at least 5 min at room temperature.
Radio-TLC analysis confirmed quantitative radiolabelling.
Small-animal PET imaging: Small-animal PET imaging was
performed on a Siemens Concorde Focus 120 microPET (Siemens). To
correct for attenuation, a 10 min transmission scan using a 57Co point
source and an energy window of 120 keV to 125 keV was performed.
Each animal was placed in a dedicated mice holder allowing for
regulated temperature control and anaesthesia delivery. Anaesthesia
was induced with 4% isoflurane in oxygen and maintained by
inhalation of 1% to 2% isoflurane. After PET imaging, structural
images for co-registration and segmentation were acquired with a
micro-CT scanner (eXplore 120, TriFoil) or 9.4 Tesla micro-MRI
(Agilent).
Tumour imaging with 18FDG: Each mouse was scanned with 2-
deoxy-2-[18F] fluoro-D-glucose (18FDG) maximum one week before
imaging with the 68Ga-radiolabelled HER2 aptamers. Mice were fasted
overnight with free access to water. The animals were warmed (30°C to
34°C) for 30 min before the acquisition and throughout the uptake and
imaging period in order to reduce tracer uptake in fat brown tissue. A
solution of 10 MBq 18FDG was injected intraperitoneally. A 10 min
static PET scan was performed 60 min p.i. Subsequently, mice were
scanned by CT. Following image reconstruction, microPET and CT
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images were manually co-registered using the commercially available
research software π.PMOD (version 3.6, PMOD Technologies) [27,28].
Tumour imaging with 68Ga-radiolabelled HER2 aptamers: Mice
were injected in the tail-vein with the 68Ga-radiolabelled HER2
aptamer HeA2_3 (n=6), HeA2_1 (n=9) or negative control aptamer
(n=6). Injections were performed using a 10 MBq solution of 68Ga-
radiolabelled HER2 aptamer. Unlabelled aptamer was added to the
solution to reach a total of 1 nmol aptamer. Dynamic scanning was
performed for 60 min immediately post injection (p.i.). Subsequently,
mice were scanned by MRI. Following image reconstruction,
microPET and MRI images were manually co-registered using the
commercially available research software π.PMOD (version 3.6,
PMOD Technologies).
PET Quantitative Analysis of 68Ga-radiolabelled aptamer
concentration: Quantitation was performed with π.PMOD (version
3.6, PMOD Technologies). To quantify radioactivity within the
tumours and main organs, regions-of-interest (ROIs) were manually
drawn in representative organ data spaces relative to visual anatomic
landmarks. Standardised uptake values (SUVs) were calculated by
dividing the tracer activity per unit mass by the amount of injected
activity per unit body mass, assuming a density of 1 g/cm3.
Ex vivo biodistribution of the 68Ga-radiolabelled aptamer: Organ
and tumour harvesting was performed 105.4 ± 11.7 min p.i. of the
68Ga-radiolabelled HER2 aptamers. The tissues were weighed
(NewClassic ML, Mettles Toledo) and counted for radioactivity using a
gamma well counter (Cobra II Auto-Gamma, Perkin-Elmer). All
measurements were decay-corrected and normalized to the total
injected activity. The tissue radioactivity was expressed as a mean ± SD
% injected dose (ID)/g tissue. These data were further used to calculate
tumour-to-background ratios. Significant differences were evaluated
by two-way ANOVA (Graphpad).
Blood perfusion assay: A blood perfusion assay was performed 90
min p.i. of the 68Ga-radiolabelled aptamer in non-tumour bearing
NOD.Cg-PrkdcscidHrhr/NCrHsd mouse. The mouse was anaesthetized
with sodium pentobarbital (Nembutal) and injected intracardially with
heparin solution (25 units per mL of 0.9% NaCl). Next, the mouse was
perfused with PBS into the left ventricle for 3 min at 12 mL/min using
a syringe pump. Afterward, the mouse was dissected and the main
organs were harvested and measured for radioactivity as described
above.
Blood collection: Whole blood was collected in Microtainer Blood
Collection Tubes containing Lithium Heparin/ PST Gel (Becton
Dickinson). Next, the tube was centrifuged for 2 min at 6,800 rpm
(Bioblock Scientific, Sigma 2-15 centrifuge) to separate the plasma
from the blood cells. For protein precipitation, an equal volume of
100% acetonitrile was added to the plasma to separate the serum from
the blood proteins. The solution was vortexed and centrifuged for 2
min at 25,000 rpm (Avanti 30 centrifuge, Analis). The amount of
radioactivity in the whole blood, plasma, blood cells, serum and blood
proteins was measured using a gamma well counter (Cobra II Auto-
Gamma, Perkin-Elmer).
Results and Discussion
Plasma stability of aptamer HeA2_3
In vivo applications of aptamers require that they remain stable in
physiological conditions for a substantial amount of time. In general,
DNA oligonucleotides are susceptible to nuclease-mediated
degradation in vivo with a half-life varying from 30 min to 60 min
[29]. In order to avoid 5’ and 3’ exonuclease activity, aptamers can be
chemically modified at their terminal ends. We evaluated the in vitro
stability of aptamer HeA2_3 bearing a 5’ NOTA modification or a 5’
NOTA modification combined with a 3’ inverted thymidine (T)
modification. After 12 h of incubation in isolated mouse plasma, the
samples were analysed by denaturing PAGE gel electrophoresis. The
results were quantified (Bio-1-D software) and the biological half-life
was estimated by fitting the data using a non-linear one-phase decay
model.
Figure 1: (A) Separation of the aptamer samples by denaturing PAGE gel electrophoresis following incubation (0 min to 720 min) in isolated
mouse plasma at 37°C. The samples which were incubated from 0 min to 90 min are presented (B) The mean ± SEM% intact aptamer (relative
to time point 0) was plotted as a function of the incubation time (log min) (0 min to 720 min) and fitted using a non-linear one-phase decay
model (GraphPad). Significance was tested by Two-way ANOVA. No significance was observed.
As shown in Figure 1A, the intensity of the band (representing the
amount of intact aptamer) decreases with time, indicating degradation
of the full-length product (40-mer). The biological half-life of the
unmodified aptamer was about two hours (121.9 min ± 45.1 min)
(Figure 1B). Protecting the 5’ end by conjugation to maleimide-NOTA
considerably improved the biological half-life (162.1 min ± 57.1 min).
Finally, addition of an extra 3’ terminal cap (inverted T) to the 5’
NOTA-conjugated aptamer further increased stability (biological half-
life of 184.6 min ± 21.5 min). These findings indicate that protection of
the 5’ and 3’ ends by functional or chemical groups considerably
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improves the aptamer stability against nuclease-mediated degradation
in mouse plasma, and therefore makes the aptamer suitable for in vivo
use. We continued our study with the 5’ NOTA conjugated aptamer
(without inverted T), since the biological half-life is sufficiently for
68Ga studies (physical half-life=68 min) and since the addition of more
modifications may change the aptamer structure, binding capacity and
function. The NOTA chelator will be used for complexation of 68Ga
(see further).
Mouse model
We developed a mouse model bearing a different tumour (i.e. one
HER2-positive and one HER2-negative tumour) at each flank. This
approach provides an ideal negative control and enables easy
comparison between the two tumours. In addition, it allows reducing
the total amount of animals. We used the recently developed hairless
NOD.SCID mouse model (NOD.Cg-PrkdcscidHrhr/NCrHsd mouse, or
commonly named SCID hairless NOD (SHrN™, HarlanLaboratories)) [30,31]. This mouse model is ideal for tumour
xenografting because the mice are triple-immunodeficient and hairless
(enabling easy visual inspection of subcutaneous tumour xenografts).
A pilot study was performed to evaluate tumour growth of several
HER2-positive and HER2-negative cell lines. Mice were injected
subcutaneously with various concentrations of SKOV3, SKBR3 or
MDA-MB-231 cells in Matrigel.
Tumour growth was externally measured using a digital calliper.
Although xenografting of SKBR3 cells has been established previously
in other mouse models [32-34], no tumour growth of the SKRB3
xenografts could be observed in the SCID hairless NOD mice. We
noticed faster tumour growth for the SKOV3 xenografts versus the
MDA-MB-231 xenografts (data not shown).
Therefore, we decided to inject a higher number of MDA-MB-231
cells (3 × 106 cells) and at an earlier time point than the SKOV3 cells
(1.5 × 106 cells). Figure 2 shows the experimental set-up, including
tumour cell injections, 18F-FDG PET/CT scan and 68Ga-radiolabelled
HER2 aptamer PET/MRI scan. All mice were analysed at the same age.
Tissue biodistribution
The tissue biodistribution of the 68Ga-radiolabelled HER2 aptamers
HeA2_3, HeA2_1 and a negative control aptamer was examined in
tumour-bearing mice. All three aptamers showed relatively high
uptake in the main organs, except the brain (Figure 3).
The lower uptake in the brain may reflect no access of the 68Ga-
radiolabelled HER2 aptamer to the brain because of the blood-brain
barrier (BBB). This result is in accordance with previous studies which
showed that aptamers are not able to cross the BBB passively [35-37].
Figure 2: Flowchart of the experimental set-up. The time of tumour xenografting, 18FDG scanning and 68Ga-radiolabelled aptamer scanning
are presented.
There were no significant differences between the two HER2
aptamers and the negative control aptamer, except a significant
increase in kidney uptake for the negative control aptamer, which may
be related to the difference in nucleotide sequence and therefore
difference in hydrophilicity.
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Figure 3: Ex vivo tissue biodistribution in tumour-xenografted mice. Analysis at 105.4 ± 11.7 min p.i., data are expressed as mean ± SD% ID/g,
n=9 (aptamer HeA2_1) and n=6 (aptamer HeA2_3 and negative control aptamer). Significant differences between the three aptamers per
organ or tissue was tested by Two-way ANOVA, p<0.001 (***).
The high uptake in the main organs may correspond to the presence
of radioactivity in the blood in these organs. Therefore, we performed
a blood perfusion assay using non-tumour bearing mice in order to
wash out the blood in the organs. As such, it gives an idea about the
actual tissue uptake in the main organs, which may be masked by the
presence of the radioactivity in the blood.
Figure 4A confirms that the main uptake in the organs was due to
the presence of the radioactivity in the blood. Figure 4A also reveals
low uptake in all organs after blood perfusion, which indicates low
non-specific binding to the tissue.
This suggests that aptamers may be advantageous to proteinous
imaging agents, which often have high non-specific uptake in the
kidneys (e.g. nanobodies) [38] and intestine (e.g. nanofittins) (own
observations). We did not observe bone accumulation after blood
perfusion which also confirms the stability of the radiolabelled
complex, since free 68Ga is known to accumulate in the bone when
released from the chelator [39].
In order to analyse the radioactivity in the blood in more detail, we
separated the whole blood into plasma, blood cells, serum and blood
proteins, and analysed the radioactivity in each fraction. Figure 4B
shows that the entire (100%) radioactivity in the whole blood
(expressed as % ID/g) was present in the plasma, of which 17.3%
remained present in the serum. As such, the radioactivity in the blood
was mainly present on the blood proteins.
The biological half-life of the (unlabelled) aptamer in plasma is
162.1 min ± 57.1 min (Figure 1B). As such, we expected that about one
fourth of the injected aptamers is metabolised after 90 min. Therefore,
a part of the observed radioactivity in the blood may originate from
radioactive metabolites.
We previously showed in vitro that no transchelation of 68Ga from
the 68Ga-radiolabelled aptamers to transferrin or serum proteins
occurred [26]. Therefore, the high radioactivity in the blood proteins
may be explained by non-specific aptamer binding to blood proteins
such as the highly abundant albumins and globulins. These blood
proteins are well-known to bind oligonucleotides in a non-specific
manner [40-42].
The same behaviour has also been observed for a variety of drugs,
such as aspirin [43,44]. Pre- or co-infusion with a non-targeting
aptamer may be used to saturate blood proteins. Another reason for
the high radioactivity in the blood may be the (specific) binding of the
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aptamer to soluble HER2 protein in blood circulation. The presence of
soluble HER2 has been observed in approximately 18% of HER2-
positive cancer patients, and is caused by shedding of the extracellular
domain of the membrane-bound HER2 receptor [45,46].
Figure 4: (A) Ex vivo tissue biodistribution in non-tumour-xenografted mice with and without perfusion. (B) Analysis of the radioactivity in
different blood fractions. Analysis 90 min p.i. of the 68Ga-radiolabelled negative control aptamer, data are expressed as mean % ID/g tissue, n=
1.
Figure 5: 18FDG analysis of tumour metabolic activity by PET/CT static scanning. The mouse bears the MDA-MB-231 tumour at the right
flank and the SKOV3 tumour at the left flank.
Tumour uptake
Ex vivo biodistribution revealed high uptake for both 68Ga-
radiolabelled HER2 aptamers in the SKOV3 tumour (7.9 ± 2.1% ID/g
for aptamer HeA2_3 and 7.1 ± 1% ID/g for aptamer HeA2_1) (Figure
3). In addition, both 68Ga-radiolabelled HER2 aptamers show a 1.5-
fold higher uptake in HER2-positive tumour (SKOV3 tumour) versus
the HER2-negative tumour (MDA-MB-231 tumour).
However, the same behaviour was observed for the negative control
aptamer and no significant differences in SKOV3 tumour uptake could
be observed between the HER2 aptamers (HeA2_1 and HeA2_3) and
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the negative control aptamer. These results suggest that tumour uptake
was more related to the tumour composition factors (such as cellular
composition, EC matrix, vascular network, lymphatic system and
necrosis) than to the expression of HER2.
18FDG PET scanning revealed heterogeneous 18FDG uptake due to
tumour necrosis. We observed more often necrotic centres in the
MDA-MB-231 tumours versus SKOV3 tumours. This may explain the
lower uptake of the 68Ga-radiolabelled aptamers in the MDA-MB-231
tumours. These results also demonstrate the importance of analysing
the xenografted tumours by 18FDG PET.
We evaluated the kinetic behaviour of the 68Ga-radiolabelled
aptamers using dynamic PET scanning. Regions of interest were drawn
on the bladder, liver, kidney, paravertebral muscle and on both
tumours. Analysis of the heart region was not possible because this was
located out of the imaging field. At multiple selected time points, the
data were extracted from time-activity curves and the SUV values were
calculated. Figure 5 shows the SUV values of 68Ga-radiolabelled
aptamer HeA2_1. Aptamer HeA2_3 and negative control aptamer had
a similar behaviour.
Figure 5A shows rapid tissue (liver and kidney) accumulation and
gradual release, reflecting renal and hepatobiliary clearance.
Accumulation in the bladder also indicates renal clearance. While the
radioactivity in the main tissues (liver, kidney and muscle) decreases in
time (Figure 5A), we observed rapid tumour uptake which slowly
continued to increase in time (Figure 5B).
We hypothesize that the long residence time of the 68Ga-
radiolabelled aptamers in the blood (as described above) leads to this
accumulation in tumour tissue. This also suggests that the affinity of
the 68Ga-radiolabelled aptamers for the tumour tissue is higher than
for the blood proteins.
In contrast to the SKOV3 tumour, the MDA-MB-231 tumour
seemed to have reached a maximum uptake after 32.5 min. This
suggests saturation of (non-specific) receptors and binding sites in the
tumour tissue. The persistent increase of accumulation in the SKOV3
tumour may reflect additional (specific) HER2 binding. Further
investigation using later time points of analysis are needed in order to
evaluate this. An increasing accumulation of radiolabelled aptamer in
time (up to 5 h p.i.) has been often observed with other aptamers
[19,20,47-49].
From these experiments, it is not possible to evaluate (specific)
tumour binding capacity of the 68Ga-radiolabelled aptamers, since this
may be masked by the high (non-specific) binding to blood proteins.
We previously confirmed the HER2 expression level of both tumours,
as well as specific binding of (fluorescently labelled) HER2 aptamers to
HER2-positive tumour tissue sections [24]. However, these in vitro
experiments were performed in the absence of blood proteins.
Therefore, a blood perfusion assay on tumour-bearing mice is
recommended to confirm specific binding of the 68Ga-radiolabelled
aptamers to the tumour xenografts in vivo.
Conclusion
The goal of this study was to evaluate the general biodistribution
profile of two novel HER2 aptamers and to demonstrate the feasibility
of these 68Ga-radiolabelled HER2 aptamers for imaging of HER2-
positive tumours. Ex vivo biodistribution analysis of the 68Ga-
radiolabelled aptamers revealed high uptake in the blood, tissues and
organs, except the brain. Preliminary results from a blood perfusion
assay suggested that the uptake in the tissues and organs was due to the
presence of radioactivity in the blood. Analysis of the radioactivity in
the different blood fractions showed that the major part of
radioactivity was present in the blood proteins. In contrast to the rapid
uptake and gradual release of radioactivity in the kidney, liver and
muscle, we observed accumulation of radioactivity in both tumours in
time. However, no significant differences between both tumour types
and between the HER2 aptamers and the negative control aptamer
could be observed.
The slow clearance from the blood stream may be an issue regarding
the signal-to-noise ratio and the overall quality of PET images, but
may be good for tumour targeting. The main future challenge of
aptamers (and oligonucleotides in general) is mastering the non-
specific interactions in vivo [41,50]. Non-specific interactions are
certainly the major pitfall for specific imaging of biological targets with
aptamers, as it results in a high background noise and therefore low
image contrast. In addition, high specificity is important to avoid false-
positive diagnoses. For therapy, the concentration of aptamer at the
target site is much more important than the signal-to-noise ratio.
Therefore, non-specific interactions are less crucial for therapeutic
applications, as long as it doesn’t lead to adverse side effects.
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